Home Embolx Inc.

Embolx Inc.

FDA Clearance of Next Generation Sniper Balloon Occlusion Microcatheter to Deliver Pressure-Directed Therapy for Tumors, Enlarged Prostate and Fibroids Announced by Embolx

6/28/18: “Our next generation devices incorporate experience from more than 1,000 Sniper balloon occlusion microcatheters used to date,” said Michael Allen, president and CEO of Embolx. “Now, interventional radiologists can do everything they would do with standard microcatheters, but with the added benefits of balloon occlusion. This is a big step forward and provides physicians with the most advanced transarterial delivery system for tumor and prostate treatment."